Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies

NCT07791199 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07791199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07791199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
October 31, 2030
Enrollment
2,300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis, psoriatic arthritis, sjögren's disease, systemic lupus erythematosus